Cipla beats Ranbaxy, tops sales in September
Ending Ranbaxy Laboratories's run as the top-selling drug maker in the domestic retail market for the last three months, Cipla has topped the retail sales chart in September. According to the market research firm ORG IMS latest figures, during September, Cipla's sales grew 15.3% from last month, garnering 4.92% in the Rs 29,000 domestic retail market. In comparison, sales of India's largest drug maker Ranbaxy Laboratories by revenue (including overseas sales), grew marginally 0.9% with a market share of 4.81%.
Ranbaxy Laboratories has been leading the sales for the last three months - June to August. GlaxoSmithkline is in the third position. India's largest company by market capitalisation, Sun Pharma, is in the 7th position with 3.08% while Hyderabad-based Dr Reddy's Laboratories, India's second-largest company by revenue (including overseas sales), lies at the 13th spot with 2.24%.
For the nine-month period ended September, Cipla continues to maintain the top spot having pipped Ranbaxy Laboratories in May. ORG IMS figures are arrived at by collecting sales figures from around thousands of pharma retail centres across the country. The Indian domestic market is around Rs 35,000 crore and growing at 13% annually. Retail sales account for around Rs 29,000 crore while the rest comes from institutional sales.
In the brands section, Pfizer's multivitamin Becosules emerged as the highest selling brand in the Indian market during the September raking in Rs 1.47 crore. Last month's highest selling cough syrup Corex, was down -18.9% from last month. Another cough syrup, Nicholas Piramal India Ltd's Phensedyl has taken the third spot. Himalaya Herbal Healthcare's liver tonic drug Liv 52, the only herbal drug in top 30 brands, is in the fourth position.
For the nine-month period ended September, Novartis painkiller Voveran continues to retain the number 1 spot having taken over Corex recently.
November 05, 2007